Structural bioinformatic approaches to the discovery of new antimycobacterial drugs

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3195-3211

  Kantardjieff, Katherine ^a   Rupp, Bernhard ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Mycobacteria; Structural bioinformatics; Structure based drug design; Tuberculosis; Virtual screening

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; 4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ANTIMYCOBACTERIAL AGENT; EFLORNITHINE DERIVATIVE; ENZYME INHIBITOR; ETHAMBUTOL; ETHIONAMIDE; GENZ 10850; GENZ 8575; GLUCOSE 1 PHOSPHATE THYMIDYLYLTRANSFERASE INHIBITOR; INDOLE DERIVATIVE; ISOCITRATE LYASE INHIBITOR; ISONIAZID; MALATE SYNTHASE INHIBITOR; METALLOPROTEINASE INHIBITOR; METHOTREXATE; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; NEW DRUG; PEPTIDE DEFORMYLASE INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; RCV 0467; RCV 11837C; RV 0467; RV 11837C; THIOUREA DERIVATIVE; TRIMETHOPRIM; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DERIVATIVE; VRC 4232; VRC 4307;

BIOINFORMATICS; CATALYSIS; DRUG DESIGN; DRUG INFORMATION; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE TARGETING; MATHEMATICAL COMPUTING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; VALIDATION PROCESS; VIRTUAL REALITY; X RAY ANALYSIS;

ANTI-BACTERIAL AGENTS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL; TUBERCULOSIS;

EID: 4644371689     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383205     Document Type: Review

References (160)

1. Baker D, Sali A. Protein structure prediction and structural genomics. Science 2001; 294: 93-6.
2. Lipinski CA. In BIOTEC PDD symposium, AAPS: Miami, FL, 1995.
3. Lipinski CA. Drug-like properties and the causes of poor solubility and permeability. J Pharmacol Toxicol 2000; 44: 235-49.
4. Walters WP, Ajay Murcko MA. Recognizing molecules with drug-like properties. Curr Opin Chem Biol 1999; 3: 384-87.
5. Oprea TI. Property distribution of drug-related chemical databases. J Comput Aided Mol Des 2000; 14: 251-64.
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
7. Blundell TL, Mizuguchi K. Structural genomics: an overview. Prog Biophys Mol Biol 2000; 73: 289-95.
8. Yon J, Jothi H. High throughput structural genomics and proteomics: where are we now? Targets 2003; 2: 201-7.
9. WHO. Tuberculosis on the increase. World Health Forum 1993; 14: 1-94.
10. Smith I. Mycobacterium tuberculosis and molecular determinants of virulence. Clin Microbiol Rev 2003; 16: 463-96.
11. Davies J. Bacteria on the rampage. Nature 1996; 383: 219-20.
12. Laing RO, McGoldrick K. In World Tuberculosis Day at Boston University School of Public Health: Boston, MA, 2000.
13. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow strain: Stategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-46.
14. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
15. Tekaia F, Gordon S, Garnier T, Brosch R, Barrell B, Cole S. Analysis of the protcome of Mycobacterium tuberculosis in silico. Tuber Lung Dis 1999; 79: 329-42.
16. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-30.
17. Zhang Y, Heym B, Allen B, Young D, Cole ST. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-93.
18. Sensi P. History of the development of rifampin. Rev Infect Dis 1983; 3: 402-6.
19. Dougherty TL, Barrett JF, Pucci MJ. Microbial genomics and novel antibiotic discovery: new technology to search for new drugs. Curr Pharm Des 2002; 8: 1119-35.
20. Diekema DI, Jones RN. Oxazolidinones: a review. Drugs. 2000; 59: 7-16.
21. Schapira M, Raaka BM, Das S, Totrov M, Zhou Z, Wilson SR, et al. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc Natl Acad Sci USA 2003; 100: 7354-59.
22. Abagyan R, Totrov M, Kuznetsov D. ICM: a new method for protein modeling and design. Applications to docking and structure prediction from the distorted native conformation. J Comp Chem 1994; 15: 488-506.
23. Schapira M, Abagyan R, Totrov M. Nuclear hormone receptor targeted virtual screening. J Med Chem 2003; 46: 3045-59.
24. Abagyan R, Totrov M. High-throughput docking for lead generation. Curr Opin Chem Biol 2001; 5: 375-82.
25. Muegge I, Rarey M. Small molecule docking and scoring. Rev Comp Chem 2001; 17: 1-60.
26. Halperin I, Ma B, Wolfson H, Nussinov R. Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins 2002; 47: 409-43.
27. Kissinger CR, Gehlhaar DK, Smith BA, Bouzida D. Molecular replacement by evolutionary search. Acta Crystallogr 2001; 57: 1474-9.
28. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
29. Camus JC, Pryor MJ, Medigue C, Cole ST. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002; 148: 2967-73.
30. Cole ST, Eigelmeier K, Parkill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007-11.
31. Garnier T, Eigelmeier K, Camus JC, Medina N, Mansoor H, Pryor MJ, et al. The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci USA 2003; 100: 7877-82.
32. Brennan MJ, Delogu G. The PE multigene family: a 'molecular mantra' for mycobacteria. Trends Microbiol 2002; 10: 246-8.
33. Gamieldien J, Ptitsyn A, Hide W. Eukaryotic genes in Mycobacterium tuberculosis could have a role in pathogenesis and immunomodulation. Trends Genet 2002; 18: 5-8.
34. Westbrook J, Feng Z, Chen L, Yang H, Berman HM. The Protein Data Bank and structural genomics. Nucleic Acids Res 2000; 31: 489-91.
35. Sanchez R, Sali A. Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol Biol 2000; 143: 97-129.
36. Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 2003; 32: 335-73.
37. Chen YZ, Zhi DG. Ligand-protein inverse docking and its use in the computer search of protein targets of a small molecule. Proteins 2001; 43: 217-26.
38. Fernandez-Recio J, Totrov M, Abagyan R. ICM-DISCO docking by global energy optimizaton with fully flexible side-chains. Proteins 2003; 52: 113-7.
39. Gray JJ, Moughon S, Wang C, Schueler-Furman O, Kuhlman B, Rohl CA, et al. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol 2003; 331: 281-99.
40. Chen YZ, Zhi DG. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001; 43: 217-26.
41. Mendez R, Leplae R, De Maria L, Wodak SJ. Assessment of blind predictions of protein-protein interactions: current status of docking methods. Proteins 2003; 52: 51-67.
42. Kremer L, Baulard AR, Besra GS. In: Hatfull G, Jacobs WR Jr Eds, Molecular Genetics of Mycobacteria. Washington DC, ASM Press, 2000; 173-90.
43. Daffe M, Draper P. The envelop layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 1998; 39: 131-203.
44. Crick DC, Brennan PJ. Antituberculosis drug research. Curr Opin Anti-Inf Invest Drugs 2000; 2: 154-63.
45. Schroeder EK, de Souza N, Santos DS, Blanchard JS, Basso LA. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr Pharm Biotech 2002; 3: 197-225.
46. Brennen PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995; 64: 29-63.
47. Belanger AE, Inamine JM. In: Hatfull G, Jacobs WR Jr Eds, Molecular Genetics of Mycobacteria. Washington DC, ASM Press, 2000; 191-202.
48. Bernstein J, Jambor WP, Lott WA, Pansy F, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. VI. Derivatives of isoniazid. Am Rev Tuberc 1953; 67: 354-65.
49. Bernstein J, Jambor WP, Lott WA, Pansy F, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. VII. Heterocyclic acid hydrazides and derivatives. Am Rev Tuberc 1953; 67: 366-75.
50. Middlebrook G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am Rev Tuberc 1954; 69: 471-72.
51. Johnsson K, Schultz PG. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994; 116: 7425-26.
52. Johnsson K, King DS, Schultz PG. Studies of the mechanism of action of isoniazid and thionamide in the chemotherapy of tuberculosis. J Am Chem Soc 1995; 117: 5009-10.
53. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restructed array of mutations associated with drug resistance. J Infect Dis 1996; 173: 196-202.
54. Bloch K. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. Adv Enzymol Relat Areas Mol Biol 1977; 45: 1-84.
55. Waller RF, Keeling PJ, Donald RG, Striepen B, Handman E, Lang-Unnasch N, et al. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc Natl Acad Sci USA 1998; 95: 12352-57.
56. Geiter LJ. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2002; 4: 221-7.
57. Wayne LG, Lin KY. Glyoxalate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982; 37: 1042-49.
58. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-69.
59. Dessen A, Quemard A, Blanchard JS, Jacobs WR Jr, Sacchettini JC. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995; 267: 1638-41.
60. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279: 98-102.
61. Rozwarski DA, Vilcheze C, Sugantino M. Bittman R, Sacchettini JC. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J Biol Chem 1999; 274: 15582-89.
62. Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase. J Biol Chem 2003; 278: 20851-59.
63. Roujeinikova A, Sedelnikova SE, de Boer GJ, Stuitje AR, Slabas AR, Rafferty JB, et al. Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition. J Biol Chem 1999; 274: 30811-17.
64. Baldock C, Rafferty JB, Sedelnikova SE, Baker PJ, Stuitje AR, Slabas AR, et al. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 1996; 274: 2107-10.
65. Perozzo R, Kuo M, Sidhu AS, Valiyaveettil JT, Bittman R, Jacobs WR Jr, et al. Structural elucidation of the specificity of the antibacterial agent triclosan for malaria enoyl acyl carrier protein reductase. J Biol Chem 2002; 277: 13106-114.
66. McLeod R, Muench SP, Rafferty JB, Kyle DE, Mui EJ, Kirisits MJ, et al. Triclosan inhibits the growth of plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J Parasitol 2001; 31: 109-13.
67. Grassberger MA, Turnowsky F, Hildebrandt J. Preparation and antibacterial activities of new 1, 2, 3-diazaborine derivatives and analogues. J Med Chem 1984; 27: 947-53.
68. Quemard A, Laneelle G, Lacave C. Mycolic acid biosynthesis: a target for ehtionamide in mycobacteria. Antimicrob Agents Chemother 1992; 36: 1316-21.
69. Winder FG. In: Ratledge C, Stanford J Eds, The Biology of the Mycobacteria. Orlando, FA, Academic Press. 1982; 353-438.
70. Stevens GJ, Hitchcock K, Wang YK, Coppola GM, Versace RW, Chin JA, et al. In vitro metabolism of N-(5-chloro-2-methylphenyl)-N′-(2-methylpropyl)thiourea: species comparison and identification od a novel thiocarbamide-glutathione adduct. Chem Res Toxicol 1997; 10: 733-41.
71. de Barber AE, Mdluli K, Bosman M, Bekker LG, Barry CE. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97: 9677-82.
72. Nelson DR. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 1999; 369: 1-10.
73. Phetsuksiri B, Baulard AR, Cooper AM, Minnikin DE, Douglas JD, Besra GS, et al. Antimycobacterial activities of isoxyl and new derivatives through inhibition of mycolic acid biosynthesis. Antimicrob Agents Chemother 1999; 43: 1042-51.
74. Nunn P, Porter J, Whitstanley P. Thiacetazone-avoid like poison or use with care? Trans R Soc Trop Med Hyg 1993; 87: 578-82.
75. Decker CJ, Doerge DR. Covalent binding of 14C- and 35S-labeled thiocarbamides in rat hepatic microsomes. Pharmacol 1992; 43: 881-88.
76. Hunter AL, Neal RA. Inhibition of hepatic mixed-function oxidase activity in vitro and in vivo by various thiono-sulfur-containing compounds. Biochem Pharmacol 1975; 24: 2199-205.
77. Tan TH, The KS, Yang SY, Tan LS, Ko HL, Tjie HB, et al. Studies on cross-resistance between isoniazid, isoxyl, teebazone, ethionamide and ethambutol of tubercle bacilli from patients never treated with those drugs except with isoniazid. Paediatr Indones 1966; 6: 32-8.
78. Osato T, Tsukagoshi K, Shimizu H. Studies on thiacetazone resistance of tubercle bacilli. 3. Cross resistance between thiacetazone and ethionamide. Kekkaku 1971; 46: 89-92.
79. Pavelka MS, Jacobs WR Jr. Biosynthesis of diaminopimelate, the precursor of lysine and a component of peptidoglycan, is an essential function of Mycobacterium smegmatis. J Bacteriol 1996; 178: 6496-507.
80. Almrud JJ, Oliveira MA, Kern AD, Grishin NV, Phillips MA, Hacked ML. Crystal structure of human ornithine decarboxylase at 2.1 A resolution: structural insights to antizyme binding. J Mol Biol 2000; 295: 7-16.
81. Jackson LK, Goldsmith EJ, Phillips MA. X-ray structure determination of Trypanosoma brucei ornithine decarbxylase bound to D-ornithine and to G418: insights into substrate binding and ODC conformational flexibility. J Biol Chem 2003; 278: 22037-43.
82. Grishin NV, Osterman AL, Brooks HB, Phillips MA, Goldsmith EJ. X-ray structure of ornithine decarboxylase from Trypanosoma brucei: The native structure and the structure in complex with a-difluoromethylornithine. Biochemistry 1999; 38: 15174-84.
83. Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 1980; 210: 332-4.
84. Gokulan K, Rupp B, Pavelka MS, Jacobs WR Jr, Sacchettini JC. Crystal structure of Mycobacterium tuberculosis diaminopimelate decarboxylase, an essential enzyme in bacteria lysine synthesis. J Biol Chem 2003; 278: 18588-96.
85. Clements JM, Beckett RP, Brown A, Catlin G, Lobell M, Palan S, et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 2001; 45: 563-70.
86. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 2000; 39: 1256-62.
87. Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T. An unusual peptide deformylase in the human mitochondrial N-terminal nethionine excision pathway. J Biol Chem 2003; 278: 52953-63.
88. Giglione C, Serero A, Pierre M, Boisson B, Meinnel T. Indentification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J 2000; 19: 5916-29.
89. Apfel C, Banner DW, Bur D, Dietz M, Hirata T, Hubschwerlen C, et al. Hydroxamic acid derivatives as potent deformylase inhibitors and antibacterial agents. J Med Chem 2000; 43: 2324-31.
90. Becker A, Schlichting i, Kabsch W, Groche D, Schultz S, Wagner AFV. Iron center, substrate recognition and mechanism of peptide deformylase. Nat Struct Biol 1998; 5: 1053-58.
91. Hao B, Gong W, Rajagopalan PT, Zhou Y, Pei D, Chan MK. Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry 1999; 38: 4712-9.
92. Kumar A, Nguyen KT, Srivathsan S, Ornstein B, Turley S, Hirsh I, et al. Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure 2002; 10: 357-67.
93. Leung D, Abbenante G, Fairlie DP. Protease inhibitors: Current status and future prospects. J Med Chem 1999; 43: 305-41.
94. Hackbarth CJ, Chen DZ, Lewis JG, Clark K, Mangold BL, Cramer JA, et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 2002; 46: 2752-64.
95. Meinnel T, Patiny L, Ragusa S, Blanquet S. Design and synthesis of substrate analoge inhibitors of peptide deformylase. Biochemistry 1999; 38: 4287-95.
96. Durand DJ, Green BG, O'Connell JF, Grant SK. Peptide aldehyde inhibitors of bacterial peptide deformylases. Arch Biochem Biophys 1999; 367: 297-302.
97. Umezawa H, Aoyagi T, Tanaka T, Suda H, Okuyama A, Naganawa H, et al. Production of actinonin, an inhibitor of aminopeptidase M, by actinomycetes. J Antibiot (Toyko) 1985; 38: 1629-30.
98. Giglione C, Vallon O, Meinnel T. Control of protein life-span by N-terminal methionine excision. EMBO J 2003; 22: 13-23.
99. Pei D. Peptide deformylase: a target for novel antibiotics? Emerg Ther Targets 2001; 5: 23-40.
100. Chan MK, Gong W, Rajagopalan PTR, Hao B, Tsai CM, Pei D. Crystal structure of Escherichia coli peptide deformylase. Biochemistry 1997; 36: 13904-09.
101. Browner MF, Smith WW, Castelhano AL. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995; 34: 6602-10.
102. Hu YJ, Wei Y, Zhou Y, Rajagopalan PT., Pei D. Determination of substrate specificity for peptide deformylase through the screening of a combinatorial peptide library. Biochemistry 1999; 38: 643-50.
103. Hu X, Nguyen KT, Verlinde CL, Hol WG, Pei D. Structure-based design of a macrocyclic inhibitor of peptide deformylase. J Med Chem 2003; 46: 3771-4.
104. Rajagopalan PT, Pei D. Oxygen-mediated inactivation of peptide deformylase. J Biol Chem 1998; 273: 22305-10.
105. Rajagopalan PT, Grimme S, Pei D. Characterization of cobalt(II)-substituted peptide deformylase: function of the metal ion and the catalytic residue Glu-133. Biochemistry 2000; 39: 779-90.
106. Yuan Z, Trias J, White RJ. Deformylase as a novel antibacterial target. Drug Discov Today 2001; 6: 954-61.
107. Nguyen KT, Hu X, Colton C, Chakrabarti R, Zhu MX, Pei D. Characterization of human peptide deformylase: implications for antibacterial drug design. Biochemistry 2003; 42: 9952-8.
108. Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen DZ, Yuan Z, et al. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother 2000; 44: 1825-32.
109. Apfel C, Locher H, Evers S, Takacs B, Hubschwerlen C, Pirson W, et al. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob Agents Chemother 2001; 45: 1058-64.
110. Newton DT, Creuzenet C, Mangroo D. Formylation is not essential for initiation of protein synthesis in all eubacteria. J Biol Chem 1999; 274: 22143-6.
111. Mazel D, Pochet S, Marliere P. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J 1994; 13: 914-23.
112. Elliott SD, Tai JY. The type-specific polysaccharides of Streptococcus suis. J Exp Med 1978; 148: 1699-704.
113. McNeil M, Daffe M, Brennan PJ. Evidence for the nature of the link between the arabinogalactan and peptidoglycan components of the mycobacterial cell walls. J Biol Chem 1990; 265: 18200-6.
114. Deng L, Mikusova K, Robuck KG, Scherman M, Brennan PJ, McNeil MR. Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob Agents Chemother 1995; 39: 694-701.
115. Graninger M, Nidetzky B, Heinrichs DE, Whitfield C, Messner PJ. Chatacterization of the DTDP-4-dehydrorhamnose 3, 5-epimerase and dTDP-4pdehydrorhamnose reductase, required for dTDP-L-rhamnose biosynthesis in Salmonella enterica serovar Typhimurium LT2. J Biol Chem 1999; 274: 25069-77.
116. Ma Y, Mills JA, Belisle JT, Vissa V, Howell M, Bowlin K, et al. Determination of the pathway for rhamnose biosynthesis in mycobacteria: cloning, sequencing and expression of the Mycobacterium tuberculosis gene encoding a-D-glucode-1-phosphate thymidylyltransferase. Microbiology 1997; 143: 937-45.
117. Blankenfeldt W, Asuncion M, Lam JS, Naismith JH. The structural basis of the catalytic mechanism and regulation of glucose-1-phosphate thymidylyltransferase (RmlA). EMBO J 2000; 19: 6652-63.
118. Allard ST, Giraud MF, Whitfield C, Graninger M, Messner PJ, Naismith JH. The crystal structure of dTDP-D-Glucose 4.6-dehydratase (RmlB) from Salmonella enterica serovar Typhimurium, the second enzyme in the dTDP-L-rhamnose pathway. J Mol Biol 2001; 307: 283-95.
119. Allard ST, Beis K, Giraud MF, Hegeman AD, Gross JW, Wilmouth WC, et al. Towards a structural understanding of the dehydratase mechanism. Structure 2002; 10: 81-92.
120. Christendat D, Saridakis V, Dharamsi A, Bochkarev A, Pai E, Arrowsmith CH, et al. Crystal structure of dTDP-4-keto-6-deoxy-D0-hexulose 3, 5-epimerase from Methanobacterium thermoautotrophicum complexed with dTDP. J Biol Chem 2000; 275: 24608-12.
121. Giraud MF, Leonard GA, Field RA, Berlind C, Naismith JH. RmlC, the third enzyme of dTDP-L-rhamnose pathway, is a new class of epimerase. Nat Struct Biol 2000; 7: 398-402.
122. Dong C, Major LL, Allen AG, Blankenfeldt W, Maskell DJ, Naismith JH. High-resolution structures of RmlC from Streptococcus suis in complex with substrate analogs locate the active site of thie class of enzyme. Structure 2003; 11: 715-23.
123. Blankenfeldt W, Kerr ID, Giraud MF, McMiken HJ, Leonard GA, Whitfield C, et al. Variation on a theme of SDR. dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) shows a new Mg2+ dependent dimerization mode. Structure 2002; 10: 773-86.
124. Babaoglu K, Page MA, Jones VC, McNeil MR, Dong C, Naismith JH, et al. Novel inhibitors of an emerging target in Mycobacterium tuberculosis; Substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg Med Chem Lett 2003; 13: 3227-30.
125. Ma Y, Stern RJ, Scherman MS, Vissa VD, Yan W, Jones VC, et al. Drug targetting Mycobacterium tuberculosis cell wall biosynthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 2001; 45: 1407-16.
126. Pan F, Jackson M, Ma Y, McNeil M. Determination that the cell wall galactofuran synthesis is essential for growth of mycobacteria. J Bacteriol 2001; 178: 1047-52.
127. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutaol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989; 33: 1493-9.
128. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996; 93: 11919-24.
129. Holm L, Sander C. Protein structure comparison by alignment of distance matrices. J Mol Biol 1983; 233: 123-38.
130. Sanders DA, Staines AG, McMahon SA, McNeil MR, Whitfield C, Naismith JH. UDP-galactopyranose mutase has a novel structure and mechanism. Nat Struct Biol 2001; 8: 858-63.
131. Fullerton SW, Daff S, Sanders DA, Ingledew WJ, Whitfield C, Chapman SK, et al. Potentiometric analysis of UDP-galatopyranose mutase: Stablization of the flavosemiquinone by substrate. Biochemistry 2003; 42: 2104-9.
132. Barlow JN, Girvin ME, Blanchard JS. Positional isotope exchange catalyzed by UDP-galactopyranose mutase. J Am Chem Soc 1999; 121: 6968-9.
133. Togo H, He W, Waki Y, Yokoyama M. C-glycosylation technology with free radical reactions. Synlett 1998; 7: 700-17.
134. Soltero-Higgin M, Carlson EE, Gruber TD, Kiessling LL. A unique catalytic mechanism for UDP-galactopyranose mutase. Nat Struct Mol Biol 2004; 11: 539-543.
135. Scherman MS, Winans KA, Stern RJ, Jones VC, Bertozzi CR, McNeil MR. Drug targeting Mycobacterium tuberculosis cell wall synthesis: development of a microtiter plate-based screen for UDp-galactospyranose mutase and identification of an inhibitor from a uridine based library. Antimicrob Agents Chemother 2003; 47: 378-82.
136. McKinney JD, Hoener zu Bentrup K, Munos-Elias EJ, Miczak A, Chen B, Chan W-T, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxalate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-8.
137. Sharma V, Sharma S, Hoener zu Bentrup K, McKinney JD, Russell DG, Jacobs WR Jr, et al. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 2000; 7: 663-8.
138. Britton KL, Abersinghe IS, Baker PJ, Barynin V, Diehl P, Langridge SJ. The structure and domain organization of Escherichia coli isocitrate lyase. Acta Crystallogr 2001; 57: 1209-18.
139. Martinussen J, Schallert J, Andersen B, Hammer K. The pyrimidine operon pyrRPB-car-A from Lactococcus lactis. J Bacteriol 2001; 183: 2785-94.
140. Nyka W. Studies on the effects of starvation on mycobacteria. Infect Immun 1974; 9: 843-50.
141. Rodriguez G, Voskuil MI, Gold B, Schoolnik K, Smith I. IdeR, an essential gene in Mycobacterium tuberculosis: Role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun 2002; 70: 3371-81.
142. Chan K, Knaak T, Satkamp L, Humbert O, Falkow S, Ramakrishnan L. Complex pattern of Mycobacterium marinum gene expression during long-term granulomatous infection. Proc Natl Acad Sci USA 2002; 99: 3920-25.
143. Tomchick DR, Turner RJ, Switzer RL, Smith JL. Adaptation of an enzyme to regulatory function: structure of Bacillus subtilis PyrR, a pyr RNA-binding attentuation protein and uracil phosphoribosyltransferase. Structure 1998; 6: 337-50.
144. Kadziola A, Neuhard J, Larsen S. Structure of product-bound Bacillus caldolyticus uracil phosphoribosyltransferase confirms ordered sequential substrate binding. Acta Crystallogr 2002; 58: 936-45.
145. Schumacher MA, Carter D, Scott DM, Roos DS, Ullman B, Brennan RG. Crystal structures of Toxoplasma gondii phosphoribosyltransferase reveal the atomic basis of pyrimidine discrimination and prodrug binding. EMBO J 1998; 17: 3219-32.
146. Blakely RL. Eukaryotic dihydrofolate reductase. Adv Enzymol Relat Areas Mol Biol 1995; 70: 23-102.
147. Blakely RL. In: Blakely RL, Benkovic SJ Eds, Folates and Pterins. New York, Wiley, 1984, 191-253.
148. Schweitzer MR, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990; 4: 2441-52.
149. Pitts C, Bowen D, Southerland WM. Interaction energy analyses of folate analog binding to human dihydrofolate reductase: contribution of the antifolate substructural regions to complex stability. Drug Metabol Drug Interact 2000; 16: 99-121.
150. Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Queener SF. Structure-based enzyme inhibitbr design: modeling studies and crystal structure analysis of Pheumocystis carinii dihydrofolate reductase ternary complex with PT653 and NADPH. Acta Crystallogr 2002; 58: 946-54.
151. Rongbao L, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F, et al. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol 2000; 295: 307-23.
152. Matthews DA, Alden RA, Bolin JT, Freer ST, Hamlin R, Xuong N, et al. Dihydrofolate reductase: X-ray structure of the binary complex with methotrexate. Science 1977; 197: 452-5.
153. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 2002; 1: 895-910.
154. Michison DA. Mechanisms of tuberculosis chemotherapy. J Pharm Pharmacol 1997; 49: 31-6.
155. Schumann G, Mollmann U. Screening system for xenosiderophores as potential drug delivery agents in mycobacteria. Antimicrob Agents Chemother 2001; 45: 1317-22.
156. Abagyan R, Batalov S, Cardozo T, Totrov M, Webber J, Zhou Y. Homology modeling with internal coordinate mechanics: deformation zone mapping and improvements of models via conformational search. Proteins 1997; Suppl 11: 29-37.
157. Kantardjieff KA, Kim C-Y, Naranjo C, Waldo GS, Lekin T, Segelke BW, et al. Mycobacterium tuberculosis RmlC epimerase (Rv3465): a promising drug-target structure in the rhamnose pathway. Acta Crystallog 2004; D60: 895-902.
158. Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ. Genomics in anti-infective drug discovery--getting to endgame. Curr Pharm Design 2002; 8(13): 1099-118.
159. Nagaraja V, Sikder D, Jain P. DNA topoisomerase I from mycobacteria--a potential drug target. Curr Pharm Design 2002; 8(22): 1995-2007.
160. Teodoro ML, Kavraki LE. Conformational flexibility models for the receptor in structure based drug design. Curr Pharm Design 2003; 9(20): 1635-48.